Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

76.46 -1.93 (-2.46%)
Official Closing Price Updated: 4:10 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,387,926
Open 78.47
Bid (Size) 76.46 (1)
Ask (Size) 76.77 (2)
Prev. Close 78.39
Today's Range 75.93 - 78.69
52wk Range 75.96 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 4.03%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Price Over Earnings Overview: Merck & Co
Via Benzinga
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery
Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access to delivery technology. 
Via Benzinga

Performance

YTD
-22.9%
-22.9%
1 Month
-19.3%
-19.3%
3 Month
-23.3%
-23.3%
6 Month
-31.4%
-31.4%
1 Year
-39.4%
-39.4%

More News

Read More
Marjorie Taylor Greene Made Large Stock Purchases Ahead Of Trump's 90-Day Tariff Pause: Hakeem Jeffries Calls It 'Problematic'
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi, LLP
Via Business Wire
MRK Investors Have the Opportunity to Lead the Merck Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Deadline Soon: Merck & Co (MRK) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
3 Robotics Stocks That Could Benefit From U.S. Manufacturing Boom
Via MarketBeat
Topics Government World Trade
Exposures Political Tariff
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline
Via Benzinga
Topics Government Supply Chain World Trade
Exposures Political Supply Chain Tariff
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Via Chartmill
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Intellectual Property Stocks World Trade
Exposures Intellectual Property Tariff US Equities
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Why Health Care Select Sector SPDR Fund (XLV) Is Moving
Via Benzinga
Topics Government
Exposures Political
Is MERCK & CO. INC. (NYSE:MRK) a Good Fit for Dividend Investing?
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
From Pomerantz LLP
Via GlobeNewswire
2 Reasons to Like MRK (and 1 Not So Much)
Via StockStory
Topics Supply Chain
Exposures Supply Chain
Faruqi & Faruqi Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK
From Faruqi & Faruqi LLP
Via GlobeNewswire
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 76.46
When was Merck & Co last traded?
The last trade of Merck & Co was at 04/16/25 04:10 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 193.55B
How many shares of Merck & Co are outstanding?
Merck & Co has 194B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.